{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:27:18Z","timestamp":1777505238798,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Kidney Health Dis"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>While severe complications are generally uncommon with novel coronavirus disease 2019 (COVID-19) vaccine, there has been a steady increase in the number of patients presenting with nephrotic syndrome and acute kidney injury after the administration of COVID-19 vaccine. Physicians should be made aware of minimal change disease as a potential complication associated with COVID-19 vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Presenting concerns:<\/jats:title>\n                    <jats:p>A 60-year-old male without significant past medical history presented with new onset of nephrotic syndrome approximately 10 days after his first dose of Pfizer-BioNTech COVID-19 vaccine. Laboratory findings showed hypoalbuminemia (20 g\/L), elevated urine albumin\/creatinine ratio (668 mg\/mmol), and elevated creatinine of 116 \u00b5mol\/L from a baseline of 79 \u00b5mol\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>A diagnostic kidney biopsy was performed 6 weeks after the onset of the edema and approximately 8 weeks after his first dose of Pfizer-BioNTech COVID-19 vaccine. The kidney biopsy findings were consistent with minimal change disease with focal acute tubular injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was treated conservatively with ramipril 10 mg and furosemide 80 mg daily 5 weeks after the onset of swelling. Prednisone 1 mg\/kg was initiated immediately when the kidney biopsy result became available (approximately 6 weeks after the onset of edema).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient remitted with rapid weight loss starting 2 weeks post prednisone initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Novel findings:<\/jats:title>\n                    <jats:p>De novo minimal change disease with acute tubular injury is a kidney manifestation following the administration of Pfizer-BioNTech COVID-19 vaccine. Minimal change disease is potentially a rare complication of Pfizer-BioNTech COVID-19 vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20543581211058271","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:59:09Z","timestamp":1637024349000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine"],"prefix":"10.1177","volume":"8","author":[{"given":"Jessica","family":"Hanna","sequence":"first","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, St. Joseph\u2019s Healthcare Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Ingram","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, McMaster University, St. Joseph\u2019s Healthcare Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4619-2194","authenticated-orcid":false,"given":"Tiffany","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, St. Joseph\u2019s Healthcare Hamilton, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"bibr1-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.035"},{"key":"bibr2-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.007"},{"key":"bibr3-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.03.010"},{"key":"bibr4-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.06.008"},{"key":"bibr5-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.003"},{"key":"bibr6-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.07.017"},{"key":"bibr7-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.004"},{"key":"bibr8-20543581211058271","doi-asserted-by":"publisher","DOI":"10.3265\/Nefrologia.pre2012.Feb.11370"},{"issue":"3","key":"bibr9-20543581211058271","first-page":"246","volume":"54","author":"Kielstein JT","year":"2000","journal-title":"Clin Nephrol"},{"key":"bibr10-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01194-5"},{"key":"bibr11-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483"},{"key":"bibr12-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7"},{"key":"bibr13-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1177\/2054358121991684"},{"key":"bibr14-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.033"},{"key":"bibr15-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.006"},{"key":"bibr16-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.005"},{"key":"bibr17-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02889-5"},{"key":"bibr18-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.006"},{"key":"bibr19-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab215"},{"key":"bibr20-20543581211058271","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.06.004"}],"container-title":["Canadian Journal of Kidney Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581211058271","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20543581211058271","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581211058271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:24:01Z","timestamp":1777389841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20543581211058271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"alternative-id":["10.1177\/20543581211058271"],"URL":"https:\/\/doi.org\/10.1177\/20543581211058271","relation":{},"ISSN":["2054-3581","2054-3581"],"issn-type":[{"value":"2054-3581","type":"print"},{"value":"2054-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20543581211058271"}}